These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 19444908)
1. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908 [TBL] [Abstract][Full Text] [Related]
2. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308 [TBL] [Abstract][Full Text] [Related]
3. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407 [TBL] [Abstract][Full Text] [Related]
4. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859 [TBL] [Abstract][Full Text] [Related]
5. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985 [TBL] [Abstract][Full Text] [Related]
7. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015 [TBL] [Abstract][Full Text] [Related]
9. A rare population of tumor antigen-specific CD4 Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427 [TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742 [TBL] [Abstract][Full Text] [Related]
11. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370 [TBL] [Abstract][Full Text] [Related]
12. Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1. Le Gal FA; Ayyoub M; Dutoit V; Widmer V; Jäger E; Cerottini JC; Dietrich PY; Valmori D J Immunother; 2005; 28(3):252-7. PubMed ID: 15838382 [TBL] [Abstract][Full Text] [Related]
13. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376 [TBL] [Abstract][Full Text] [Related]
14. Identification of NY-ESO-1 Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF Front Immunol; 2021; 12():644520. PubMed ID: 33833762 [TBL] [Abstract][Full Text] [Related]
15. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system. Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982 [TBL] [Abstract][Full Text] [Related]
16. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757 [TBL] [Abstract][Full Text] [Related]
17. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956 [TBL] [Abstract][Full Text] [Related]
18. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423 [TBL] [Abstract][Full Text] [Related]
19. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. Bownds S; Tong-On P; Rosenberg SA; Parkhurst M J Immunother; 2001; 24(1):1-9. PubMed ID: 11211143 [TBL] [Abstract][Full Text] [Related]
20. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]